Defining extended half-life rFVIIIA critical review of the evidence
Open Access
- 1 May 2018
- journal article
- review article
- Published by Wiley in Haemophilia
- Vol. 24 (3), 348-358
- https://doi.org/10.1111/hae.13438
Abstract
IntroductionRecent haemophilia treatment advances include new recombinant FVIII (rFVIII) products with improved pharmacokinetic (PK) properties that aim to reduce the burden of prophylaxis. These treatments are commonly referred to as extended half-life rFVIII products (EHL rFVIII). There is no uniform definition of what constitutes an EHL rFVIII. Such a definition would help physicians, patients and funders understand the properties of standard and EHL rFVIIIs and thus provide clarity when selecting an EHL in clinical settings. AimTo critically assess the published evidence on new and emerging rFVIII products in order to propose a definition to classify EHL rFVIIIs. MethodsWe systematically searched PubMed, EMBASE and regulatory authorities (FDA/EMA/Health Canada) websites for publications and regulatory submissions describing prospective crossover PK studies evaluating rFVIIIs that demonstrate improved PK parameters in adults and adolescents with severe haemophilia A. ResultsFollowing critical analyses of the published data, we developed a holistic approach to defining rFVIIIs as EHLs, which requires all of the following: (i) using technology designed to extend rFVIII half-life; (ii) lacking bioequivalence with a standard rFVIII comparatorabove the FDA/EMA cut-off of 125% for the 90% confidence intervals for area under the curve ratio; and (iii) having an extended half-life ratio measured in a PK comparator crossover study. ConclusionIn this systematic review, a pragmatic definition of EHL rFVIII has been proposed that should provide better clarity in clinical discussions surrounding the appropriate use of rFVIII products. At present, only products using PEGylation or Fc fusion half-life extension technology meet the proposed criteria for definition of EHL rFVIII.Keywords
This publication has 37 references indexed in Scilit:
- Innovative coagulation factors: albumin fusion technology and recombinant single-chain factor VIIIThrombosis Research, 2013
- The first recombinant human coagulation factor VIII of human origin: human cell line and manufacturing characteristicsEuropean Journal of Haematology, 2012
- Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patientsBlood, 2012
- Factor VIII and von Willebrand factor interaction: biological, clinical and therapeutic importanceHaemophilia, 2009
- Joint outcomes in patients with haemophilia: the importance of adherence to preventive regimensHaemophilia, 2009
- The Pharmacology of PEGylation: Balancing PD with PK to Generate Novel TherapeuticsJournal of Pharmaceutical Sciences, 2008
- Safety and pharmacokinetics of a recombinant factor VIII with pegylated liposomes in severe hemophilia AJournal of Thrombosis and Haemostasis, 2008
- Clearance of von Willebrand factorThrombosis and Haemostasis, 2008
- Practice patterns in haemophilia A therapy – global progress towards optimal careHaemophilia, 2006
- A multicenter pharmacokinetic study of the B-domain deleted recombinant factor VIII concentrate using different assays and standardsJournal of Thrombosis and Haemostasis, 2003